Insight Molecular Diagnostics (IMDX) FCF Margin (2020 - 2026)

Insight Molecular Diagnostics has disclosed FCF Margin across 7 years of filings, most recently posting 25787.5% for Q1 2026.

• FCF Margin for Q1 2026 came in at 25787.5%, down 2550004.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 1409.7% (down 79827.0% YoY), and the FY2025 annual result was 625.62%, up 50170.0% from the prior year.
• FCF Margin came in at 25787.5% for Q1 2026 at Insight Molecular Diagnostics, down from 616.68% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 287.46% in Q1 2025 to a low of 25787.5% in Q1 2026.
• The 5-year median for FCF Margin is 2189.77% (2024), against an average of 4778.11%.
• Across the five-year window, FCF Margin jumped 1754396 bps in 2023 and tumbled 2550004 bps in 2026, its largest moves.
• Insight Molecular Diagnostics' FCF Margin stood at 3813.87% in 2022, then jumped by 61 bps to 1492.99% in 2023, then soared by 75 bps to 374.5% in 2024, then slumped by 65 bps to 616.68% in 2025, then slumped by 4082 bps to 25787.5% in 2026.
• The last three FCF Margin figures came in at 25787.5% (Q1 2026), 616.68% (Q4 2025), and 2135.38% (Q3 2025), per Business Quant data.